Clinical Chemistry Link to Randox Laboratories Web Site
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
 QUICK SEARCH:   [advanced]


     


Clinical Chemistry 51: 2207-2208, 2005; 10.1373/clinchem.2005.053058
This Article
Right arrow Extract Freely available
Right arrow Full Text (PDF)
Right arrow Submit an electronic Letter to
the Editor about this paper
Right arrow Alert me when this article is cited
Right arrow Alert me when eLetters are posted
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in ISI Web of Science
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via ISI Web of Science (1)
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Kalambokis, G.
Right arrow Articles by Tsianos, E. V.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Kalambokis, G.
Right arrow Articles by Tsianos, E. V.
Related Collections
Right arrow General Clinical Chemistry
Right arrow Clinical Immunology
Right arrow Proteomics and Protein Markers
Right arrow Endocrinology and Metabolism
(Clinical Chemistry. 2005;51:2207-2208.)
© 2005 American Association for Clinical Chemistry, Inc.


Letters to the Editor

Tumor Necrosis Factor-{alpha}–Related Intraperitoneal Release of CA 125 in Cirrhotic Patients with Sterile Ascites

Georgios Kalambokis, Ageliki Kostoula, Michalis Economou and Epameinondas V. Tsianosa

Departments of1 Internal Medicine2 Microbiology and3 Gastroenterology, Medical School of Ioannina, Ioannina, Greece

aAddress correspondence to this author at: Department of Internal Medicine, Medical School of Ioannina, 45110 Ioannina, Greece. Fax 30-26510-97016; e-mail geodora{at}mail.gr.


To the Editor:

Cancer antigen 125 (CA 125) (1)(2)(3) is commonly increased in liver cirrhosis and increased even more in ascitic fluid(4)(5)(6). Peritoneal mesothelial cells can synthesize CA 125(7), and proliferative mesothelial cells stain for it(8). It is not clear whether mechanical stress related to ascites can stimulate mesothelium to produce CA 125(4)(6) or whether clearance of CA 125 by the diseased liver is impaired(4)(5). Mesothelial cells may regulate intraperitoneal antibacterial defense mechanisms(9)(10)(11). Cultured mesothelial cells produce cytokines, including interleukin-6 (IL-6) and IL-8, on stimulation with tumor necrosis factor-{alpha} (TNF-{alpha}) or IL-1ß(9). Human peritoneal macrophages produce TNF-{alpha} and IL-1ß after incubation with bacteria, which in turn can trigger mesothelial cells to produce IL-8(10) and IL-6(12). High serum concentrations of TNF-{alpha} and IL-6, possibly of intraabdominal origin, have been observed in cirrhotic patients with sterile ascites(13). We investigated whether the intraperitoneal release of CA 125 in cirrhotic patients with sterile ascites could be influenced by the stimulation of mesothelial cells with proinflammatory cytokines, such as TNF-{alpha}.

We studied 72 consecutive cirrhotic patients [28 female; mean (SD) age, 54 (13) years]. We excluded patients with liver carcinoma or other neoplasms, gastrointestinal hemorrhage, systemic infections, spontaneous bacterial peritonitis (SBP), or recent antibacterial therapy (previous 2 weeks) and those receiving prophylactic norfloxacin, corticosteroid treatment, or pentoxifylline. The etiologies of cirrhosis were chronic hepatitis B (18 cases), chronic hepatitis C (9), alcohol abuse (38), and primary biliary (3) or cryptogenic (4) cirrhosis. Ascites was evaluated by ultrasonography and graded as small (<0.5 L; 20 patients; group 2), moderate (0.5–2 L; 17 patients; group 3), or large (>2 L; 15 patients; group 4) (14). No ascites was present in 20 other patients (group 1). Ascitic fluid was aspirated from all patients with ≥0.5 L of ascites. Prothrombin activity and serum concentrations of albumin, total bilirubin, and alanine aminotransferase were measured, and ascitic fluid polymorphonuclear (PMN) cells were counted. Immunoreactive CA 125 was simultaneously measured in serum and ascitic fluid (Abbott IMx; cutoff, 35 kilounits/L). We also measured TNF-{alpha} and IL-6 in serum and ascitic fluid (Bender MedSystems). Serum and ascitic fluid were centrifuged immediately after collection. For statistical analysis, we used Mann–Whitney U- and Spearman correlation tests; P <0.05 was considered significant.

We found no correlations between serum or ascitic CA 125 concentrations and prothrombin activity, albumin, total bilirubin, or alanine aminotransferase. Larger ascites volumes were associated with higher mean (SD) CA 125 concentrations: For patients with no, small, moderate, or large volumes, CA 125 was, respectively, 16.9 (12.2), 117 (62), 420 (245), and 808 (494) kilounits/L. Similarly, TNF-{alpha} concentrations were, respectively, 9.9 (4), 12.8 (4), 15.4 (4.6), and 21.4 (7.2) ng/L, and IL-6 concentrations were 9.5 (3.3), 26.2 (3.9), 47.3 (6.9), and 53 (8) ng/L. Differences were significant except for differences in TNF-{alpha} between groups 3 and 2 and in IL-6 values between groups 4 and 3. Patients with large ascites had significantly higher ascitic concentrations of CA 125 than patients with moderate ascites [1181 (648) vs 682 (404) kilounits/L], whereas differences in the ascitic concentrations of TNF-{alpha} and IL-6 and PMN cell count were not significant. The ascitic concentrations of CA 125, TNF-{alpha}, and IL-6 were always higher than the corresponding serum concentrations and correlated significantly with the serum concentrations. The mean ascitic concentrations of CA 125, TNF-{alpha}, and IL-6 were significantly higher than the mean serum values in groups 3 and 4. Serum CA 125 was statistically significantly correlated with the ascitic PMN cell count and serum TNF-{alpha} and IL-6 concentrations (Fig. 1 ). In addition, correlations between ascitic concentrations of CA 125 and PMN cell count, between ascitic concentrations of TNF-{alpha} and IL-6, and between serum and ascitic concentrations of TNF-{alpha} and IL-6 and ascitic PMN cell count were statistically significant.



View larger version (10K):
[in this window]
[in a new window]
 
Figure 1. Correlations between serum CA 125 concentrations and ascitic PMN cell count (A), serum TNF-{alpha} (B), and serum IL-6 (C).

(A), r = 0.81; P <0.001; (B), r = 0.79; P <0.001; (C), r = 0.82; P <0.001.

Subclinical activation of ascitic fluid defense mechanisms from previous silent colonization by bacteria has been suggested in cirrhotic patients (13)(15). Indeed, higher baseline serum concentrations of TNF-{alpha} and IL-6 have been observed in cirrhotic patients with sterile ascites than in patients without ascites(16). In addition, cirrhotic patients who subsequently develop SBP appear to have higher serum TNF-{alpha} concentrations and PMN cell counts in the sterile ascitic fluid than patients who do not(13). An intraabdominal origin of TNF-{alpha} and IL-6 is most likely because the concentrations of these cytokines are markedly higher in the ascitic fluid than in blood(13)(14)(17). Of interest, SBP has been associated with extreme increases in circulating TNF-{alpha} and IL-6(14)(16), as well as with the highest concentrations of CA 125(4).

CA 125 is commonly increased in decompensated cirrhotic patients in proportion to the degree of ascites, and has been proposed as a sensitive marker for the detection of ascites in these patients (5). The results of the present study do not exclude the contribution of ascites-related mechanical stress of the mesothelium to the increased release of CA 125 in cirrhosis. On the other hand, our observations suggest an association between the subclinical activation of peritoneal defense mechanisms in cirrhotic patients with ascites and the production of CA 125 by the mesothelial cells. Further studies are needed to investigate the mechanisms underlying the stimulation of CA 125 synthesis by TNF-{alpha}, and possibly by other cytokines, as well as whether repeated measurements of serum CA 125 could be of value as a reflection of ascitic fluid bacterial activity in cirrhotic patients with sterile ascites.


References

  1. Bast RC, Jr, Klug TL, St John E, Jenison E, Niloff JM, Lazarus H, et al. A radioimmunoassay using a monoclonal antibody to monitor the course of epithelial ovarian cancer. N Engl J Med 1983;309:883-887.[Abstract]
  2. Jacobs I, Bast RC. The CA-125 tumor-associated antigen: a review of the literature. Hum Reprod 1989;4:1-12.[Abstract/Free Full Text]
  3. Miralles C, Orea M, Espana P, Provencio M, Sánchez A, Cantos B, et al. Cancer antigen 125 associated with multiple benign and malignant pathologies. Ann Surg Oncol 2003;10:150-154.[Abstract/Free Full Text]
  4. Molina R, Filella X, Bruix J, Mengual P, Bosch J, Calvet X, et al. Cancer antigen 125 in serum and ascitic fluid of patients with liver diseases. Clin Chem 1991;37:1379-1383.[Abstract/Free Full Text]
  5. Zuckerman E, Lanir A, Sabo E, Rosenvald-Zuckerman T, Matter I, Yeshurun D, et al. Cancer antigen 125: a sensitive marker of ascites in patients with liver cirrhosis. Am J Gastroenterol 1999;94:1613-1618.[CrossRef][ISI][Medline] [Order article via Infotrieve]
  6. Sari R, Yildirim B, Sevinc A, Hilmioglu F, Zuckerman , et al. Sensitivity of CA-125 in patients with liver cirrhosis in the presence of ascites. [Erratum in Am J Gastroenterol 2001;96:1319]Am J Gastroenterol 2001;96:253-254.[ISI][Medline] [Order article via Infotrieve]
  7. Kabawat CE, Bast RC, Bhan AK, Welch WR, Knapp RC, Colvin RB. Tissue distribution of a coelomic-epithelium-related antigen recognized by the monoclonal antibody OC125. Int J Gynecol Pathol 1983;2:275-285.[ISI][Medline] [Order article via Infotrieve]
  8. Mezger J, Lamerz R, Arnholdt H, Huhn D, Wilmanns W. Tumor markers in the diagnosis of ascitic and pleural puncture fluids. Onkologie 1986;9:11-16.
  9. Topley N, Jorres A, Luttmann W, Petersen MM, Lang MJ, Thierauch KH, et al. Human peritoneal mesothelial cells synthesize interleukin-6: induction by IL 1 and TNF. Kidney Int 1993;43:226-233.[ISI][Medline] [Order article via Infotrieve]
  10. Betjes MGH, Tuk CW, Struijk DG, Krediet RT, Arisz L, Hart M, et al. Interleukin-8 production by human peritoneal mesothelial cells in response to TNF{alpha}, IL 1 and medium conditioned by macrophages co-cultured with Staphylococcus epidermidis. J Infect Dis 1993;168:1202-1210.[ISI][Medline] [Order article via Infotrieve]
  11. Topley N, Williams JD. Role of the peritoneal membrane in the control of inflammation in the peritoneal cavity. Kidney Int 1994;46:S71-S78.
  12. Maher JC, Friedman SL. Parenchymal and nonparenchymal cell interaction in the liver. Semin Liver Dis 1993;13:13-20.[ISI][Medline] [Order article via Infotrieve]
  13. Such J, Hillebrand DJ, Guarner C, Berk L, Zapater P, Westengard J, et al. Tumor necrosis factor-{alpha}, interleukin-6, and nitric oxide in sterile ascitic fluid and serum from patients with cirrhosis who subsequently develop ascitic fluid infection. Dig Dis Sci 2001;46:2360-2366.[CrossRef][ISI][Medline] [Order article via Infotrieve]
  14. Dubbins PA.. The peritoneum. Cosgrove D Meire H Dewbury K eds. Clinical ultrasound, abdominal and general ultrasound, 1st ed. 1993:737-750 Churchill Livingstone London. .
  15. Rodriguez-Ramos C, Galan F, Diaz F, Elvira J, Martn-Herrera L, Girón-González JA, et al. Expression of proinflammatory cytokines and their inhibitors during the course of spontaneous bacterial peritonitis. Dig Dis Sci 2001;46:1668-1676.[CrossRef][ISI][Medline] [Order article via Infotrieve]
  16. Genesca J, Gonzalez A, Segura R, Catalan R, Marti R, Varela E, et al. Inteleukin-6, nitric oxide, and the clinical and hemodynamic alterations of patients with liver cirrhosis. Am J Gastroenterol 1999;94:169-177.[CrossRef][ISI][Medline] [Order article via Infotrieve]
  17. Zeni F, Tardy B, Vindimian M, Comtet C, Page Y, Cusey I, et al. High levels of tumor necrosis factor-{alpha} and interleukin-6 in the ascitic fluid of cirrhotic patients with spontaneous bacterial peritonitis. Clin Infect Dis 1993;17:218-223.[ISI][Medline] [Order article via Infotrieve]




This Article
Right arrow Extract Freely available
Right arrow Full Text (PDF)
Right arrow Submit an electronic Letter to
the Editor about this paper
Right arrow Alert me when this article is cited
Right arrow Alert me when eLetters are posted
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in ISI Web of Science
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via ISI Web of Science (1)
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Kalambokis, G.
Right arrow Articles by Tsianos, E. V.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Kalambokis, G.
Right arrow Articles by Tsianos, E. V.
Related Collections
Right arrow General Clinical Chemistry
Right arrow Clinical Immunology
Right arrow Proteomics and Protein Markers
Right arrow Endocrinology and Metabolism


HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS